Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaprozin
Drug ID BADD_D01635
Description Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Indications and Usage Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
Marketing Status approved
ATC Code M01AE12
DrugBank ID DB00991
KEGG ID D00463
MeSH ID D000077431
PubChem ID 4614
TTD Drug ID D0M9DC
NDC Product Code 60760-092; 63629-8724; 17349-0008; 59762-6002; 0025-1381; 60760-203; 63629-1345; 69238-1120; 61919-178; 61919-673; 71335-0617; 71335-0902; 62135-176; 55111-013; 55111-170; 60760-382; 0185-0141; 55289-601
UNII MHJ80W9LRB
Synonyms Oxaprozin | 4,5-Diphenyl-2-oxazolepropionic Acid | 4,5 Diphenyl 2 oxazolepropionic Acid | Wy-21,743 | Wy 21,743 | Daypro | Rhoxal-oxaprozin | Rhoxal oxaprozin | Apo-Oxaprozin | Apo Oxaprozin | Danoprox | Dayrun
Chemical Information
Molecular Formula C18H15NO3
CAS Registry Number 21256-18-8
SMILES C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.005302%Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Agitation19.06.02.001; 17.02.05.0120.003534%
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Bladder pain20.02.02.001--Not Available
Bleeding time prolonged13.01.02.002--Not Available
Blood pressure fluctuation24.06.01.002--Not Available
Body temperature increased13.15.01.001--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Coma17.02.09.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cystitis20.03.02.002; 11.01.14.001--
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Depressed level of consciousness17.02.04.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages